Entire cohort (N = 119) | N of patients | N of events | Hazard ratio | 95 % CI | Wald’s p |
---|---|---|---|---|---|
 Performance status | |||||
  1–2–3 vs. 0 | 32 vs. 87 | 27 vs. 61 | 1.64 | 1.03–2.62 | 0.036 |
 TOP2A (FISH) ratio 2.0 copies 4.0 | |||||
  Amplified vs. non-amplified | 42 vs. 77 | 28 vs. 60 | 0.62 | 0.38–1.00 | 0.050 |
 MYC CN | |||||
  Gain vs. no gain | 10 vs. 109 | 10 vs. 78 | 6.02 | 2.67–13.6 | <0.001 |
 Type of disease*CEN profile (binary) |  |  |  |  | 0.048 |
  CEN profile, 1chr vs. other @ R-mBC | 28 vs. 58 | 24 vs. 39 | 2.29 | 1.36–3.85 |  |
  CEN profile, 1chr vs. other @ de novo-mBC | 12 vs. 21 | 9 vs. 16 | 0.77 | 0.29–2.04 |  |
  de novo-mBC vs. R-mBC @ CEN profile, other | 21 vs. 58 | 16 vs. 39 | 1.15 | 0.64–2.08 |  |
  de novo-mBC vs. R-mBC @ CEN profile, 1chr | 12 vs. 28 | 9 vs. 24 | 0.39 | 0.16–0.93 |  |
HER2-positive (N = 83) | |||||
 TOP2A (FISH) ratio 2.0 copies 4.0 | |||||
  Amplified vs. non-amplified | 39 vs. 44 | 25 vs. 35 | 0.58 | 0.35–0.98 | 0.041 |
 MYC CN | |||||
  Gain vs. no gain | 7 vs. 76 | 7 vs. 53 | 4.40 | 1.90–10.2 | 0.001 |
HER2-negative (N = 45) | |||||
 Menopausal status | |||||
  Post vs. pre | 28 vs. 17 | 25 vs. 10 | 3.69 | 1.57–8.65 | 0.003 |
 ER/PgR | |||||
  Positive vs. negative | 39 vs. 6 | 29 vs. 6 | 0.22 | 0.08–0.58 | 0.002 |
 MYC FISH binary (ratio 2, copies >5) | |||||
  Amplified vs. non-amplified | 4 vs. 41 | 4 vs. 31 | 4.54 | 1.40–14.70 | 0.012 |
 Ki67 (by increase 5 %) |  |  | 1.16 | 1.07–1.26 | 0.001 |
R-mBC (N = 84) | |||||
 Age | |||||
  ≥50 vs. <50 | 56 vs. 28 | 39 vs. 23 | 0.50 | 0.28–0.89 | 0.019 |
 Performance status | |||||
  1-2-3 vs. 0 | 25 vs. 59 | 22 vs. 40 | 1.83 | 1.07–3.14 | 0.028 |
 ER/PgR | |||||
  Positive vs. negative | 57 vs. 27 | 39 vs. 23 | 0.43 | 0.24–0.76 | 0.004 |
 PI3K | |||||
  Activation vs. non-activation | 74 vs. 10 | 56 vs. 6 | 4.50 | 1.63–12.39 | 0.004 |
 MYC CN | |||||
  Gain vs. no gain | 6 vs. 78 | 6 vs. 56 | 20.48 | 6.77–61.99 | <0.001 |
de novo-mBC (N = 49) | |||||
 Performance status | |||||
  1-2-3 vs. 0 | 13 vs. 36 | 12 vs. 26 | 1.99 | 0.99–4.02 | 0.055 |
 ER/PgR | |||||
  Positive vs. negative | 36 vs. 13 | 27 vs. 11 | 0.16 | 0.03–0.77 | 0.023 |
 HER2 status/subtypes |  |  |  |  | 0.13 |
  Luminal HER2 vs. HER2-negative | 21 vs. 17 | 16 vs. 13 | 1.15 | 0.53–2.49 | 0.72 |
  HER-enriched vs. HER2-negative | 11 vs. 17 | 9 vs. 13 | 0.20 | 0.04–0.96 | 0.045 |